ClinicalTrials.gg
TerminatedNCT01620944Updated Jan 10, 2024Results posted

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

A Phase 3 interventional study of Atazanavir and Ritonavir in HIV, sponsored by Bristol-Myers Squibb. Terminated. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-10.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Why this study was terminated
Business objectives have changed

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study in antiretroviral (ARV)-naïve Human immunodeficiency virus 1 (HIV-1) ribonucleic acid infected subjects is to compare the response rate at Week 48 of a daily regimen of Atazanavir (ATV)/ Ritonavir (RTV)HS 300/100 mg combined with either one additional drug [Lamivudine (3TC) 300 mg daily] or 2 additional drugs [Tenofovir/Emtricitabine(TDF/FTC) 300/200 mg daily].

02

Conditions studied

  • HIV
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed Written .

i) Freely given informed consent must be obtained from subjects prior to clinical trial participation, including informed consent for any screening procedures conducted to establish subject eligibility for the trial.

ii) A freely given Pharmacokinetics (PK) sub-study consent form must be obtained from the subset of subjects participating in the intensive PK sub-study.

  • Target Population.

i) Treatment-naive -1-infected subjects (\< 48 hours of any ARV is allowed).

ii) Subjects who have an HIV-1 Ribonucleic acid (RNA) level ≥ 1000 c/mL at screening.

iii) Subjects who have a Antigenic marker of helper/inducer T lymphocytes (CD4) + cell count > 100 cells/mm3.

  • Age and Reproductive Status.

i) Men and women, 18 years of age or older (or minimum age as determined by local regulatory or legal requirements).

ii) Women of (WOCBP) must use highly effective methods of for up to 8 weeks after the last dose of product to minimize the risk of pregnancy. WOCBP must follow instructions for birth control for the entire duration of the study including a minimum of 30 days after dosing has been completed.

iii) Acceptable methods of highly effective birth control include:.

A. Condom with spermicide.

B. Diaphragm and spermicide.

C. Cervical cap and spermicide

  • Since acceptable and available methods of contraception vary among different countries, participating women may choose their preferred contraceptive method atazanavir AI424494 BMS-232632 Clinical Protocol Date: 31-01-2012 33 based on physician recommendations. Caution is warranted with co-administration of oral contraceptives (ethinyl estradiol and norethindrone).

i) Women must have a negative serum or urine pregnancy test [minimum sensitivity 25 IU/L or equivalent units of Human chorionic gonadotropin (HCG)] within 24 hours prior to the start of investigational product.

ii) Women must not be breastfeeding.

iii) Sexually active fertile men must use highly effective birth control if their partners are WOCBP.

Exclusion criteria

Exclusion Criteria

  • Target Disease Exceptions.

i) Subjects who have an -1 RNA level ≥500,000 c/mL at screening.

ii) Screening HIV genotype showing resistance to any component of the study regimen (ATV, RTV, 3TC, TDF/FTC).

iii) Previously documented HIV-2 infection.

  • Medical History and Concurrent Diseases.

i) Acute or chronic virus (HBV) or Acute virus (HCV) co-infection.

  • Note Chronic co-infection with hepatitis C is not exclusion criteria. Subjects with acute hepatitis C may have the option to be screened after the event has evolved into a chronic infection.

i) Presence of a newly diagnosed HIV-related opportunistic infection (OI) or any medical condition requiring acute therapy at the time of enrollment. Subjects on stable maintenance therapy for an OI may be enrolled.

ii) Primary HIV infection.

iii) History or current cardiac disease, defined by presence of arrhythmias, ischemic disease, or a conduction abnormality including left bundle branch block (LBB) or left anterior fascicular block (LAFB), 2nd or 3rd-degree atrioventricular block (AVB), or any cardiac abnormality deemed by the investigator. In addition, the following (ECG) findings are exclusionary:.

A. PR Interval > 260 msec (severe 1st degree AV Block).

B. QRS Interval > 120 msec.

iv) Moderate-to-severe hepatic insufficiency.

v) Obstructive liver disease.

vi) Recent therapy with agents having significant systemic myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic or cytotoxic potential within 3 months of study start or the expected need for such therapy at the time of enrollment, or therapy with methadone or ribavirin/interferons or treatment with neurotoxic drugs or drugs that affect .

vii) Concomitant administration of a proton pump inhibitor (PPI) or H2 blocker or any other drug with potential interaction with the products.

viii) \< 1 year according to the judgment of the investigator.

ix) Active alcohol or substance use sufficient, in the investigator's opinion, to prevent adequate compliance with study therapy or to increase the risk of developing pancreatitis or chemical hepatitis.

x) History or ongoing psychiatry disorder.

xi) Any other clinical conditions or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for study or unable to comply with the dosing requirements.

  • Physical and Laboratory Test Findings.

i) Screening laboratory analysis shows any of the following abnormal laboratory results:.

A. Grade IV glucose.

B. Grade IV electrolytes.

C. Grade IV transaminases.

D. Grade IV hematology.

ii) Calculated \< 60 mL/min as estimated by the Cockcroft-Gault equation.

  • Allergies and Adverse Drug Reaction.

    i) to any component of the study drug formulations.

  • Sex and Reproductive Status.

    i) Pregnancy.

  • Other protocol-defined Inclusion/Exclusion criteria apply.

    i) Prisoners or subjects who are involuntarily incarcerated.

ii) Subjects who are compulsorily detained for treatment of either a psychiatric or physical (eg, infectious disease) illness.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Arm1: ATV/RTVHS+3TC

    Drug: Atazanavir · Drug: Ritonavir · Drug: Lamivudine

  • Active comparator
    Arm2: ATV/RTVHS+TDF/FTC

    Drug: Atazanavir · Drug: Ritonavir · Drug: Tenofovir/Emtricitabine

Interventions

  • Capsule, oral, 300 mg, Once daily (QD), 96 weeks

  • Tablets, oral, 100 mg, QD, 96 Weeks

    Also known as: Ritonavir high sensitivity (RTV HS)

  • Tablet, oral, 300 mg, QD, 96 Weeks

  • DrugTenofovir/Emtricitabine

    Drug pages: Tenofovir · Emtricitabine

    Tablets, oral, 300/200 mg, QD, 48 Weeks

06

What researchers measure

Primary outcomes

  1. Proportion of Participants With HIV-1 RNA < 40 c/mL at Week 48

    Proportion of subjects with HIV-1 RNA \< 40 c/mL at Week 48.

    Time frame: Week 48

Secondary outcomes

  1. Proportion of Participants With HIV-1 RNA < 400 c/mL at Week 48

    Proportion of Participants with HIV-1 RNA \< 400 c/mL at Week 48.

    Time frame: Week 48

  2. Proportion of Participants With HIV-1 RNA < 40 c/mL and < 400 c/mL at Week 96

    proportion of subjects with HIV-1 RNA \< 40 c/mL and \< 400 c/mL at Week 96.

    Time frame: Week 96

  3. Incidence of Adverse Events Through Weeks 48 and 96

    Incidence of Adverse Events through weeks 48 and 96 including serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation. There were no SAEs or AEs reported in this early terminated study.

    Time frame: through weeks 48 and 96

  4. Percent Change From Baseline in eGFR and Bone Mineral Density at Weeks 48 and 96

    Percent change from baseline in eGFR and bone mineral density at weeks 48 and 96.

    Time frame: Weeks 48 and 96

  5. Incidence of Newly Emergent Genotypic Substitutions and Phenotypic Resistance to Study Drugs for Virologic Failures Through Week 48 and 96

    Incidence of newly emergent genotypic substitutions and phenotypic resistance to study drugs for virologic failures through Week 48 and 96.

    Time frame: Through week 48 and 96

07

Results

Posted Aug 6, 2021

Participant flow

Participant flow — Overall Study
MilestoneArm AArm B
Started21
Completed00
Not completed21
Withdrew: Early termination of study21

Outcome measures

PrimaryProportion of Participants With HIV-1 RNA < 40 c/mL at Week 48

Proportion of subjects with HIV-1 RNA \< 40 c/mL at Week 48.

Time frame:
Week 48

No measurements were reported for this outcome.

SecondaryProportion of Participants With HIV-1 RNA < 400 c/mL at Week 48

Proportion of Participants with HIV-1 RNA \< 400 c/mL at Week 48.

Time frame:
Week 48

No measurements were reported for this outcome.

SecondaryProportion of Participants With HIV-1 RNA < 40 c/mL and < 400 c/mL at Week 96

proportion of subjects with HIV-1 RNA \< 40 c/mL and \< 400 c/mL at Week 96.

Time frame:
Week 96

No measurements were reported for this outcome.

SecondaryIncidence of Adverse Events Through Weeks 48 and 96

Incidence of Adverse Events through weeks 48 and 96 including serious adverse events (SAEs) and adverse events (AEs) leading to discontinuation. There were no SAEs or AEs reported in this early terminated study.

Time frame:
through weeks 48 and 96

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline in eGFR and Bone Mineral Density at Weeks 48 and 96

Percent change from baseline in eGFR and bone mineral density at weeks 48 and 96.

Time frame:
Weeks 48 and 96

No measurements were reported for this outcome.

SecondaryIncidence of Newly Emergent Genotypic Substitutions and Phenotypic Resistance to Study Drugs for Virologic Failures Through Week 48 and 96

Incidence of newly emergent genotypic substitutions and phenotypic resistance to study drugs for virologic failures through Week 48 and 96.

Time frame:
Through week 48 and 96

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A—0/2 (0%)0/2 (0%)
Arm B—0/1 (0%)0/1 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Arm AArm BTotal
<=18 years000
Between 18 and 65 years213
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Arm AArm BTotal
Female000
Male213
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm AArm BTotal
Hispanic or Latino000
Not Hispanic or Latino213
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm AArm BTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American101
White112
More than one race000
Unknown or Not Reported000
08

Study locations

No study locations are listed for this record.

09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2012 to primary completion in Jan 2013, 5 months.

Results were first posted in Aug 2021, 8 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2012
First posted
Jun 15, 2012
StartActual
Jul 31, 2012
Primary completionActual
Jan 22, 2013
CompletionActual
Jan 22, 2013
Results first posted
Aug 6, 2021
Last update
Jan 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01620944
Responsible party
Sponsor
First posted
Jun 15, 2012
Start date
Jul 31, 2012
Primary completion
Jan 22, 2013
Completion
Jan 22, 2013
Results posted
Aug 6, 2021
Last update
Jan 10, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamivudine

Start the discussion